Hepatocellular carcinoma (HCC) is a primary malignancy of the liver that commonly arises from underlying liver cirrhosis. Nexavar (Bayer HealthCare...
Colorectal cancer is the third-most-common cancer globally, and metastatic disease is associated with poor five-year overall survival rates. Current...
Seven premium-priced therapies (Avastin, Erbitux, Vectibix, Zaltrap, Stivarga, Lonsurf, and Cyramza) and three immune checkpoint inhibitors (...
Building on the success of the PD-1 inhibitor Opdivo (Bristol-Myers Squibb / Ono Pharmaceutical) in the recurrent renal cell carcinoma setting,...
The 2016/17 FDA ap...
For decades, the treatment landscape of small-cell lung cancer (SCLC) has been dominated by chemotherapy or chemoradiotherapy. In 2018, Bristol-...
Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and...
Treatment for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) has remained relatively unchanged in t...
DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key soft tissue sarcoma patien...
DRG Epidemiology’s coverage of soft tissue sarcoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We...
The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy was the standard of care for ovarian cancer; however,...
Characterized by high incidence and long treatment durations, the breast cancer market represents a great commercial opportunity for drug developers...
Non-small-cell lung cancer (NSCLC)—the leading cause of cancer-related deaths in China—has a highly dynamic drug development pipeline, with...
Immune checkpoint inhibitors have transformed the treatment algorithm for recurrent or metastatic non-nasopharyngeal squamous cell carcinoma of the...
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.
The incidence of gastroesophageal cancer—encompassing gastric cancer, esophageal cancer, and gastroesophageal junction (GEJ) adenocarcinoma—...
COMING SOON Breast cancer is one of the most frequently diagnosed cancers among Chinese women. A high incidence and a prolonged treatment duration...
The FDA approval of five immune checkpoint inhibitors for advanced or metastatic bladder cancer has significantly altered the treatment landscape...
Get content updates to your inbox
Subscribe